CoChat
Sign Up
Cited by 52Adrenal and Paraganglionic TumorsMedical Imaging Techniques and ApplicationsNeuroendocrine Tumor Research Advances

Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT

Hahner, Stefanie, Kreissl, Michael C., Fassnacht, Martin, Haenscheid, Heribert, Bock, Stefanie, Verburg, Frederik A., Knoedler, Pascal, Lang, Katharina +4 more·2013·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2012-3045
Open this paper in CoChat — free account

Abstract

CONTEXT: Adrenal tumors are highly prevalent and represent a wide range of different pathological entities. Conventional imaging often provides only limited information on the origin of these lesions. Novel specific imaging methods are, therefore, of great clinical interest. OBJECTIVE: We evaluated [(123)I]iodometomidate ([(123)I]IMTO) imaging for noninvasive characterization of adrenal masses. DESIGN/SETTING: This was a prospective monocentric diagnostic study in a tertiary care center. PATIENTS AND INTERVENTION: A total of 51 patients with an adrenal lesion underwent [(123)I]IMTO imaging after injection of 185 MBq of [(123)I]IMTO. Sequential planar whole-body scans until 24 hours postinjection and single photon emission computed tomography (SPECT)/computed tomography imaging 4 to 6 hours postinjection were performed. MAIN OUTCOME MEASURE: Sensitivity and specificity of [(123)I]IMTO imaging for the noninvasive characterization of adrenal lesions were measured. RESULTS: Adrenocortical tissue showed high and specific tracer uptake with a short investigation time and low radiation exposure. Qualitative analysis of SPECT/computed tomography data resulted in a sensitivity of 89% and a specificity of 85% for differentiating adrenocortical tumors from lesions of nonadrenocortical origin. Receiver-operating characteristic analysis of semiquantitative data revealed a sensitivity of 83% and a specificity of 86% for identification of adrenocortical lesions at a cutoff value of tumor to liver ratio of 1.3. CONCLUSIONS: [(123)I]IMTO is a highly specific radiotracer for imaging of adrenocortical tissue with a short investigation time and low radiation exposure. Because of the general availability of SPECT technology, [(123)I]IMTO scintigraphy has the potential to become a widely used tool to noninvasively characterize the biology of adrenal lesions.

Integrity signals

Registry

Crossref · 10.1210/jc.2012-3045

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • 123I-IMTO SPECT-CT permits highly specific characterization of adrenocortical tissue with lower radiation exposure and investigation than NP-59 scintigraphy.

    “123I-IMTO SPECT-CT permits highly specific characterization of adrenocortical tissue with lower radiation exposure and investigation than NP-59 scintigraphy (368) and also has reported value for the staging of ACC (369).”

    From Adrenal incidentaloma (2020) · cites this paper as [368]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Hahner, S., Kreissl, M. C., Fassnacht, M., Haenscheid, H., Bock, S., Verburg, F. A., Knoedler, P., Lang, K., Reiners, C., Buck, A. K., Allolio, B., & Schirbel, A.
Affiliations
  • Endocrinology and Diabetes Unit (S.H., M.F., S.B., K.L., B.A.), D-97080 Würzburg, Germany
  • Universitätsklinikum Würzburg (DE)
  • Universitätsklinikum Aachen (DE)
  • University of Würzburg (DE)
Corresponding author
Allolio, Bruno
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2013-04-01
Volume
98
Issue
4
Pages
1508-1518
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2012-3045
OpenAlex
W2098587765
Cited by
52
References
35
Citations by year
2026: 1 · 2025: 3 · 2024: 1 · 2023: 2 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 4 · 2018: 2 · 2017: 5 · 2016: 7 · 2015: 6 · 2014: 4 · 2013: 2
FWCI
6.23
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • RWTH Publications (RWTH Aachen) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Epidemiology › Neuroendocrine Tumor Research Advances
Keywords
adrenal mass, adrenal tumors, SPECT/CT, functional imaging, adrenocortical tumors, tumor-to-liver ratio, diagnostic accuracy, radiation exposure
MeSH terms
Adolescent, Adrenal Gland Neoplasms, Adult, Aged, Aged, 80 and over, Carcinoma, Etomidate, Female, Humans, Iodine Radioisotopes, Male, Middle Aged, Sensitivity and Specificity, Tomography, X-Ray Computed, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Positron-Emission Tomography, Whole Body Imaging, Young Adult, Multimodal Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review